Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled clinical study of Nilotinib (Tasigna®) in patients with Parkinson's disease

Next Previous
X
Search
Trial Profile

A double-blind, placebo-controlled clinical study of Nilotinib (Tasigna®) in patients with Parkinson's disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use

    • Most Recent Events

    • 04 Oct 2016 New trial record
    • 14 Sep 2016 According to an Inhibikase Therapeutics media release, the Investigational New Drug (IND) application filed by the company has received FDA clearance to initiate this clinical trial and should begin patient evaluation for enrollment within a few months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top